---
title: Resveratrol in SIRT1 and Other Sirtuin Modulators
description: Resveratrol role in SIRT1 activation, compounds targeting other sirtuins
  (SIRT2–SIRT7), dietary sources and therapeutic doses
created: 2026-07-02
source: https://aistudio.google.com/u/0/prompts/1kUJDpdDMR88wWnNR_7kpQlfBdqhbzW7C
tags:
  - gemini
  - clippings
  - sirtuins
  - resveratrol
  - resveratrol-sirtuin-activators
  - sirt2-sirt7-modulators
  - dietary-sirtuin-sources
aliases: []
---



# Resveratrol, Sirtuins & Dietary Sources

## Resveratrol and SIRT1

The interaction between **[[Resveratrol]]** (a natural polyphenolic compound found in grapes, berries, and red wine) and **[[SIRT1]]** (Sirtuin 1, an [[NAD+]]-dependent deacetylase) is one of the most thoroughly researched pathways in molecular biology. SIRT1 plays a vital role in regulating cellular health, metabolic homeostasis, inflammation, mitochondrial function, and aging.

Initially, the mechanism by which resveratrol activates SIRT1 was a subject of scientific controversy. However, research has clarified that resveratrol activates SIRT1 through a combination of **direct allosteric activation** and **indirect, network-based pathways**.

### The Dual Mechanism of SIRT1 Activation

Resveratrol activates SIRT1 via two primary, interconnected pathways: direct molecular binding and indirect intracellular signaling.

```
[ Resveratrol ]
                      /           \
         (Direct Pathway)       (Indirect Pathway)
                |                       |
       Binds SIRT1 NTD            Inhibits [[PDE4]]
      (e.g., [[Glu230]] residue)         |
                |                  Increases [[cAMP]]
         Allosteric change              |
                |                  Activates [[Epac1]] → Ca2+ Release
     Lowers Km for substrates           |
                |                  Activates [[AMPK]]
                |                       |
                |                  Upregulates [[NAMPT]] → Increases [[NAD+]]
                |                       |
                \                       /
                 [ Hyperactivated SIRT1 ]
```

#### A. Direct (Allosteric) Activation

Early in vitro studies showing that resveratrol directly activated SIRT1 were challenged because they utilized a non-physiological, fluorophore-labeled peptide substrate. Critics argued that the activation was an experimental artifact of the fluorescent tag.

Subsequent structural biology and biochemical studies resolved this, demonstrating that **direct allosteric activation does occur, but it is substrate-dependent**:

- **Binding Site:** Resveratrol binds to a specific region within the N-terminal domain (NTD) of SIRT1 (specifically requiring the **Glutamate 230 (E230)** residue).
- **Conformational Change:** Upon binding, resveratrol stabilizes the interaction between SIRT1's NTD and the substrate.
- **Substrate Selectivity:** This binding induces a conformational change that lowers the Michaelis constant (Km) of SIRT1 for specific target proteins. This means SIRT1 develops a much higher affinity for key physiological substrates, such as **[[PGC-1α]]** and **[[FOXO3a]]**, promoting their deacetylation even at lower baseline levels.

#### B. Indirect Activation (The AMPK-PDE Axis)

While direct binding occurs, a significant portion of resveratrol's in vivo effects is mediated indirectly by increasing cellular levels of nicotinamide adenine dinucleotide ([[NAD+]]), the obligate co-substrate for SIRT1 activity.

1. **Phosphodiesterase (PDE) Inhibition:** Resveratrol acts as a competitive inhibitor of cyclic adenosine monophosphate ([[cAMP]]) phosphodiesterases (specifically **[[PDE4]]**).
2. **cAMP Accumulation:** Inhibiting PDE prevents cAMP degradation, leading to an accumulation of intracellular cAMP.
3. **Calcium Signaling:** High cAMP activates **[[Epac1]]** (Exchange Protein directly Activated by cAMP), which triggers the release of Calcium ([[Ca2+]]) from the endoplasmic reticulum into the cytoplasm.
4. **AMPK Activation:** The surge in cytoplasmic Ca2+ activates **[[CaMKKβ]]** (calmodulin-dependent protein kinase kinase beta), which phosphorylates and activates **[[AMPK]]** (AMP-activated protein kinase).
5. **NAD+ Synthesis:** Activated AMPK increases the expression of **[[NAMPT]]** (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the [[NAD+]] salvage pathway.
6. **SIRT1 Stimulation:** The resulting boost in cellular NAD+ levels fuels SIRT1, dramatically increasing its deacetylase activity.

### Downstream Effects of SIRT1 Activation

Once activated by resveratrol, SIRT1 deacetylates several downstream transcription factors and co-activators, triggering a cascade of survival and metabolic adaptations:

#### PGC-1α (Mitochondrial Biogenesis)

- **Mechanism:** SIRT1 deacetylates **[[PGC-1α]]** (peroxisome proliferator-activated receptor-gamma coactivator 1-alpha).
- **Result:** Deacetylated PGC-1α becomes active, migrating to the nucleus to drive the transcription of nuclear and mitochondrial genes. This leads to **[[Mitochondrial Biogenesis]]**, increased oxygen consumption, and enhanced oxidative phosphorylation (OXPHOS).

#### FOXO Transcription Factors (Stress Resistance & Autophagy)

- **Mechanism:** SIRT1 deacetylates **[[FoxO1]]** and **[[FOXO3a]]**.
- **Result:** This shifts FOXO-mediated transcription away from apoptosis-inducing genes and toward stress-resistance genes. It upregulates endogenous antioxidant enzymes (such as **[[SOD2]]** and **Catalase**) and induces autophagy genes, allowing cells to clear damaged proteins and organelles.

#### NF-κB (Anti-Inflammatory Effects)

- **Mechanism:** SIRT1 deacetylates the **p65 subunit of [[NF-κB|NF-κB]]** (Nuclear Factor kappa B).
- **Result:** Deacetylation inhibits NF-κB's transcriptional activity, preventing it from binding to DNA. This downregulates the expression of pro-inflammatory cytokines (such as **TNF-α**, **IL-1β**, and **IL-6**), making resveratrol a highly potent anti-inflammatory agent.

#### p53 (Cell Survival vs. Apoptosis)

- **Mechanism:** SIRT1 deacetylates the tumor suppressor **[[p53]]**.
- **Result:** Deacetylation of p53 reduces its transcriptional activity, suppressing p53-mediated apoptosis under moderate cellular stress. This allows cells time to undergo DNA repair rather than undergoing programmed cell death.

### Therapeutic Implications

The resveratrol-SIRT1 axis has been studied extensively across several broad domains of health:

- **Metabolic Health:** By activating the AMPK/SIRT1/PGC-1α pathway, resveratrol mimics many of the physiological effects of [[Caloric Restriction]]. In animal models of diet-induced obesity, it has been shown to improve [[Insulin Sensitivity]], reduce hepatic steatosis (fatty liver), and lower blood glucose levels.
- **Cardiovascular Protection:** Endothelial SIRT1 activation by resveratrol increases the expression and activity of **eNOS** (endothelial nitric oxide synthase). This promotes nitric oxide production, resulting in vasodilation, improved blood pressure regulation, and reduced oxidative damage in vascular walls.
- **Neuroprotection:** In neurodegenerative models, resveratrol-mediated SIRT1 activation promotes the clearance of misfolded protein aggregates and enhances neuronal survival.

### Limitations and Scientific Caveats

Despite the robust biochemistry observed in laboratory settings, translating resveratrol's SIRT1-activating properties to human clinical therapies has faced significant hurdles:

> [!warning] Bioavailability Challenge
> Resveratrol is highly lipophilic and rapidly absorbed in the human gastrointestinal tract, but it undergoes extensive first-pass metabolism (rapid glucuronidation and sulfation in the gut and liver). Extremely low concentrations of free, active resveratrol reach the systemic circulation and target tissues.

1. **Hormetic (Biphasic) Effects:** Resveratrol often exhibits a biphasic dose-response curve. At low to moderate concentrations, it acts as a mild stressor that triggers beneficial adaptive responses (SIRT1 activation, antioxidant upregulation). However, at very high concentrations, it can induce off-target effects, cell cycle arrest, or pro-oxidant states depending on the cell type.
2. **Clinical Consistency:** Due to differences in formulation, dosing, and individual metabolic rates, clinical trial results have been inconsistent.

---

## SIRT2–SIRT7 Modulators

While SIRT1 is the most heavily studied member of the sirtuin family, mammals possess six other sirtuins (**[[SIRT2]] to [[SIRT7]]**) localized in distinct cellular compartments. Like SIRT1, they are all NAD+-dependent enzymes, but they exhibit diverse catalytic activities — including deacetylation, demalonylation, desuccinylation, and [[ADP-ribosylation]].

Over the years, researchers have identified several natural and synthetic compounds capable of modulating these other sirtuins. The most notable progress has been made with **[[SIRT3]]** and **[[SIRT6]]**, while others present unique structural challenges that favor inhibition rather than activation.

### SIRT3 Activators (Mitochondrial Deacetylase)

[[SIRT3]] is the primary deacetylase inside the mitochondria. It deacetylates enzymes involved in the tricarboxylic acid (TCA) cycle, fatty acid oxidation, the urea cycle, and oxidative phosphorylation.

#### Key Compounds

- **[[Honokiol]] (HKL):** A natural biphenolic lignan extracted from the bark of *Magnolia grandiflora*.
- **[[Dihydromyricetin]] (DHM):** A natural flavonoid found in plants like the *Ampelopsis grossedentata* (Vine Tea).
- **1,4-Dihydropyridines (DHPs):** Synthetic compounds engineered to allosterically activate mitochondrial sirtuins.

```
[ Honokiol / DHM ]
                             │
                             ▼
                    Binds Direct to [[SIRT3]]
                             │
            ┌────────────────┴────────────────┐
            ▼                                 ▼
    Deacetylates [[MnSOD]]            Deacetylates [[OSCP]]
            │                                 │
     Scavenges ROS /                  Boosts ATP Synthase /
    Limits Mitochondria Damage        Improves Respiration
```

#### Mechanisms of Action

- **Direct Binding and Expression:** Honokiol has been shown to physically interact with SIRT3, increasing its deacetylase activity and upregulating its protein expression.
- **Targeting MnSOD (Manganese Superoxide Dismutase):** Once activated, SIRT3 deacetylates MnSOD (at lysine residues [[Lys68]] and K122). Deacetylated MnSOD becomes highly active, converting damaging superoxide radicals into hydrogen peroxide, which dramatically lowers mitochondrial oxidative stress.
- **Enhancing ATP Synthesis:** SIRT3 deacetylates **[[OSCP]]** (oligomycin-sensitivity conferring protein), a subunit of the mitochondrial F1Fo-ATPase. This modification optimizes ATP synthase coupling, boosting cellular energy output while minimizing mitochondrial "leakage" and fission.

#### Physiological Impact

- **Cardioprotection:** Honokiol-mediated SIRT3 activation has been shown to reverse [[Cardiac Hypertrophy]] and protect heart tissue from doxorubicin-induced cardiotoxicity without blunting the drug's anti-tumor activity in preclinical models.
- **Anti-Fibrotic Effects:** In kidneys, activating SIRT3 with Honokiol suppresses the NF-κB/TGF-β1 pathway, limiting renal tubulointerstitial fibrosis.

### SIRT6 Activators (Nuclear Deacetylase & Deacylase)

[[SIRT6]] is a nuclear scaffold protein essential for DNA repair, telomere maintenance, glycolysis suppression, and genomic stability. Uniquely, SIRT6 has a very high affinity for removing long-chain fatty acyl groups (such as myristoyl and palmitoyl groups) from histones rather than simple acetyl groups.

#### Key Compounds

- **[[UBCS039]]:** The first synthetic, specific allosteric activator of SIRT6.
- **[[MDL-800]] & [[MDL-801]]:** Highly potent, cell-permeable synthetic allosteric activators of SIRT6.
- **[[Cyanidin]]:** A natural anthocyanidin (found in red berries) capable of increasing SIRT6 activity by over 50-fold in certain in vitro assays.

```
[ UBCS039 / MDL-801 / Cyanidin ]
                                │
                                ▼
               Binds Allosteric Hydrophobic Pocket
                                │
                                ▼
            Stabilizes Active Conformation of [[NAD+]]
                 and Histone Acyl Substrates
                                │
            ┌───────────────────┴───────────────────┐
            ▼                                       ▼
  Deacetylates Histones (H3K9 / H3K56)     Induces Autophagy &
            │                              Restricts Glycolysis
     Improves DNA Repair /                          │
     Maintains Genomic Stability           Suppresses Tumor Growth
```

#### Mechanisms of Action

- **Targeting the Unique Hydrophobic Pocket:** SIRT6 features a "splayed open" structure containing a distinct, elongated hydrophobic pocket designed to hold long-chain fatty acyls. Crystal structures show that **MDL-801** and **UBCS039** bind to this distal allosteric pocket.
- **Conformational Stabilization:** This binding stabilizes the catalytically active conformation of both the NAD+ co-substrate and the target acetylated/acylated peptide substrate, facilitating efficient deacetylation.
- **Epigenetic Regulation:** SIRT6 activation results in the rapid deacetylation of **H3K9ac** and **H3K56ac** on chromatin, allowing chromatin compaction and facilitating the recruitment of double-strand break repair machinery.

#### Physiological Impact

- **Oncological Regulation:** By suppressing glycolysis (the Warburg effect) and driving tumor cells toward autophagy, SIRT6 activators like UBCS039 have demonstrated tumor-suppressive activity in several cancer cell lines.
- **Organ Protection:** UBCS039 has been evaluated in models of acute liver failure, where it significantly mitigated oxidative stress and inflammatory damage in a SIRT6-dependent manner.

### SIRT5 Activators (Mitochondrial Desuccinylase & Demalonylase)

[[SIRT5]] is located in the mitochondria but possesses virtually no deacetylase activity. Instead, its catalytic pocket contains specific residues (Arg105 and Tyr102) that favor negatively charged modifications, making SIRT5 an active **desuccinylase**, **demalonylase**, and **deglutarylase**.

- **Compounds:** Specific **1,4-dihydropyridine (DHP)** derivatives have been synthesized that selectively activate SIRT5, though research on specific clinical candidates is in earlier stages compared to SIRT1, 3, and 6.
- **Mechanism & Physiological Impact:** SIRT5 activation de-succinylated **[[CPS1]]** (carbamoyl phosphate synthase 1), the rate-limiting enzyme of the urea cycle. This action regulates ammonia detoxification and maintains metabolic flux under fasting or high-protein diet conditions.

### Sirtuins Lacking Prominent Activators (SIRT2, SIRT4, SIRT7)

For the remaining sirtuins, therapeutic strategies generally focus on **inhibition** rather than activation, or direct small-molecule activation has proven difficult to achieve.

#### SIRT2 (Cytoplasmic Deacetylase)

- **The Paradigm:** SIRT2 deacetylates tubulin and plays a critical role in cell cycle progression, myelination, and myelin maintenance.
- **Inhibitors over Activators:** Direct activation of SIRT2 is rarely sought because its overactivity is associated with neurotoxicity. Instead, **SIRT2 inhibitors** (e.g., **[[AGK2]]**, **AK-7**, and **[[SirReal2]]**) are being heavily investigated for neurodegenerative diseases like Parkinson's and Huntington's, where blocking SIRT2 helps rescue microtubule stability and protects neurons from aggregation-induced toxicity.

#### SIRT4 (Mitochondrial Lipoamidase & ADP-Ribosyltransferase)

- **The Challenge:** [[SIRT4]] has incredibly weak deacetylase activity. It primarily acts to ADP-ribosylate and inhibit **[[Glutamate Dehydrogenase (GDH)|Glutamate Dehydrogenase]]**, opposing SIRT3 by downregulating insulin secretion and amino acid-stimulated metabolism.
- **Compounds:** No selective, potent direct small-molecule activators of SIRT4 are currently established.

#### SIRT7 (Nucleolar Deacetylase)

- **The Challenge:** [[SIRT7]] is highly localized to the nucleolus and deacetylates histone **H3K18** to regulate ribosome biogenesis. Due to its highly restricted, nucleolar-specific microenvironment, developing selective small-molecule activators has remained structurally challenging, with no dominant drug candidates in advanced development.

### Summary of Sirtuin Activators

| Sirtuin | Localization | Activity | Notable Activators | Key Targets / Effects |
|---------|-------------|----------|-------------------|----------------------|
| **[[SIRT1]]** | Nucleus / Cytoplasm | Deacetylation | [[Resveratrol]], [[SRT1720]] | [[PGC-1α]], [[FOXO3a]], [[NFKB\|NF-κB]]; metabolic homeostasis |
| **[[SIRT2]]** | Cytoplasm | Deacetylation | None prominent (inhibitors used) | Microtubule/tubulin regulation |
| **[[SIRT3]]** | Mitochondria | Deacetylation | [[Honokiol]], [[Dihydromyricetin]] | [[MnSOD]], [[OSCP]]; mitochondrial biogenesis, ROS reduction |
| **[[SIRT4]]** | Mitochondria | ADP-ribosylation, Lipoamidase | None prominent | GDH regulation, insulin secretion |
| **[[SIRT5]]** | Mitochondria | Desuccinylase, Demalonylase | DHP derivatives (early stage) | [[CPS1]], urea cycle regulation |
| **[[SIRT6]]** | Nucleus | Deacetylation, Deacylation | [[UBCS039]], [[MDL-801]], [[Cyanidin]] | H3K9/H3K56, DNA repair, autophagy |
| **[[SIRT7]]** | Nucleolus | Deacetylation | None prominent | H3K18, ribosome biogenesis |

> [!tip] Universal NAD+ Boosters
> To boost NAD+ levels, precursors like **NMN (Nicotinamide Mononucleotide)** and **[[NR]] (Nicotinamide Riboside)** serve as universal, indirect pan-sirtuin activators by raising the concentration of their required co-substrate.

---

## Dietary Sources & Therapeutic Doses

Translating laboratory or clinical sirtuin-activation data into daily dietary choices reveals a major disconnect for most compounds. While some sirtuin activators require consuming humanly impossible volumes of food or drink, others are surprisingly attainable through specific traditional teas and berries.

The following breakdown outlines the key dietary sources for these sirtuin modulators, the target doses used in therapeutic research, and calculations of how much food or beverage is required to reach those levels.

### Resveratrol (SIRT1 Activator)

Resveratrol is found primarily in the skins of red grapes, red wine, peanuts, cocoa, and dark berries (such as blueberries and cranberries).

- **Target Therapeutic Daily Dose:** Typically **150 mg to 500 mg** in human clinical trials focusing on metabolic and cardiovascular markers.
- **Concentration in Diet:**
  - **Red Wine:** Typically ranges from **1.5 to 3 mg per liter** (though high-altitude Malbecs or cool-climate Pinot Noirs can reach up to 5.8 mg/L). A standard 5-ounce (148 mL) glass contains roughly **0.3 mg** of trans-resveratrol.
  - **Red Grapes:** Raw red grapes contain roughly **0.15 to 1.3 mg per 100 grams** (mostly concentrated in the skins).
- **Dietary Estimate to Reach 500 mg:**
  - **Red Wine:** At an average concentration of ~1.9 mg/L, you would need to drink approximately **263 liters** (~1,778 standard glasses) of red wine.
  - **Red Grapes:** At an average concentration of ~1.08 mg/100g, you would need to consume approximately **46 kg (~102 lbs)** of fresh red grapes.

> [!danger] Not Achievable Through Diet
> **Feasibility:** Not achievable through diet or beverage. Supplementation is required for therapeutic dosing.

### Dihydromyricetin / DHM (SIRT3 Activator)

[[Dihydromyricetin]] is a flavonoid found predominantly in **Vine Tea** (also known as Rattan Tea or Teng Cha; *Ampelopsis grossedentata*), a traditional herbal beverage consumed in Southwestern China.

- **Target Therapeutic Daily Dose:** Typically **100 mg to 300 mg** (often utilized at 300 mg to 600 mg for metabolic health or liver protection).
- **Concentration in Diet:**
  - **Vine Tea Leaves:** Vine tea is exceptionally rich in DHM. Unprocessed, dry leaves contain an astonishing **20% to 30% DHM by weight**.
- **Dietary Estimate to Reach 300 mg:**
  - **Vine Tea:** Because of its high concentration, you only need to brew **1 to 1.5 grams of dry vine tea leaves** in hot water to extract a 300 mg dose of highly water-soluble DHM. This is equivalent to about **one to two standard cups** of brewed tea.

> [!success] Highly Attainable
> **Feasibility:** Highly attainable via diet. Drinking a single cup of traditional Chinese vine tea easily provides a therapeutic dose of DHM.

### Cyanidin / Cyanidin-3-Glucoside (SIRT6 Activator)

[[Cyanidin]] and its primary derivative, cyanidin-3-glucoside (C3G), are natural anthocyanidins responsible for the deep red, blue, and purple pigments in dark berries.

- **Target Therapeutic Daily Dose:** Clinical and animal extrapolations generally target **100 mg to 300 mg** of cyanidin-3-glucoside daily.
- **Concentration in Diet:**
  - **Black Elderberries:** Exceptionally concentrated, containing roughly **350 mg to 450 mg** of cyanidin-3-glucoside per 100 grams of fresh berries.
  - **Blackberries:** High concentration, averaging about **80 to 95 mg** of cyanidin-3-glucoside per 100 grams of fresh berries.
  - **Black Currants:** Highly concentrated, yielding up to **250 to 300 mg** of total anthocyanins (largely cyanidin and delphinidin derivatives) per 100 grams.
- **Dietary Estimate to Reach 300 mg:**
  - **Black Elderberries:** You would need to consume **70 to 85 grams** (slightly less than 1 cup) of fresh elderberries.
  - **Blackberries:** You would need approximately **216 to 352 grams** (roughly 1.5 to 2.5 cups) of fresh blackberries, depending on the cultivar.

> [!success] Highly Attainable
> **Feasibility:** Highly attainable via diet. A single serving of elderberries or a modest bowl of blackberries covers the therapeutic threshold.

### Honokiol (SIRT3 Activator)

[[Honokiol]] is not found in standard grocery store foods. Its primary source is the bark of the **Magnolia tree** (*Magnolia grandiflora* or *Magnolia officinalis*), which is commonly used in traditional Asian medicine as a brewed herbal decoction (tea).

- **Target Therapeutic Daily Dose:** Typically **100 mg to 300 mg** daily.
- **Concentration in Diet:**
  - **Magnolia Bark:** Dried crude bark typically contains about **1% to 5% honokiol** (alongside its structural isomer, magnolol).
- **Dietary Estimate to Reach 200 mg:**
  - **Magnolia Bark Tea:** You would need to brew and drink a strong tea made from **4 to 20 grams of raw, dried magnolia bark**.
- **Solubility Caveat:** Honokiol is highly lipophilic and has extremely poor solubility in plain water. A traditional hot-water tea will only extract a tiny fraction of the available honokiol. To achieve a therapeutic dose, it must be extracted using solvents like ethanol (tinctures) or supercritical CO2.

> [!warning] Difficult to Achieve via Tea
> **Feasibility:** Moderately difficult and biochemically active. While brewing the raw bark is possible, magnolia compounds are highly sedating and interact strongly with GABA receptors. Consuming large doses via homemade teas is difficult to standardize and may cause unwanted drowsiness, making purified extracts a safer choice.

### Summary Checklist

| Compound (Sirtuin Target) | Target Dose | Feasibility via Whole Foods | Required Daily Intake |
|---------------------------|-------------|-----------------------------|----------------------|
| **[[Resveratrol]]** (SIRT1) | 500 mg | **No** | ~1,778 glasses of red wine OR ~102 lbs of red grapes |
| **[[Dihydromyricetin]]** (SIRT3) | 300 mg | **Yes** | 1–2 cups of brewed Vine (Rattan) Tea |
| **[[Cyanidin]]** (SIRT6) | 300 mg | **Yes** | ~1 cup of elderberries OR ~2.5 cups of blackberries |
| **[[Honokiol]]** (SIRT3) | 200 mg | **Difficult** | 4–20g raw magnolia bark (poor water solubility; use extracts) |
To verify these figures, we can look at the raw chemical composition databases and the step-by-step mathematical calculations. Because natural compounds vary based on agricultural factors, soil quality, and preparation methods, these numbers represent realistic estimates rather than static, absolute values. 

The underlying data and mathematical checks for each compound are explained below.

---

### 1. Resveratrol (SIRT1)
*   **Target Dose:** 500 mg
*   **Red Wine Data:** Systematic reviews and databases (such as *Phenol-Explorer*) show that the average trans-resveratrol concentration in red wine is approximately **1.9 mg per liter** (typically ranging from 0.5 to 4.0 mg/L depending on the grape variety and skin contact time during fermentation).
    *   **Calculation:** 
        $$\frac{500\text{ mg}}{1.9\text{ mg/L}} \approx 263.15\text{ liters of wine}$$
    *   A standard US glass of wine is 5 fluid ounces (148 mL).
        $$\frac{263,150\text{ mL}}{148\text{ mL/glass}} \approx 1,778\text{ glasses}$$
*   **Red Grapes Data:** According to nutritional databases, raw black/red grapes contain an average of **1.08 mg of trans-resveratrol per 100 grams of fresh weight (FW)**, though some cultivars yield as little as 0.15 mg/100g.
    *   **Calculation (at average yield):** 
        $$\frac{500\text{ mg}}{1.08\text{ mg/100g}} = 46,296\text{ grams} \approx 46.3\text{ kg (102 lbs)}$$
    *   **Calculation (at lower yield of 0.15 mg/100g):** 
        $$\frac{500\text{ mg}}{0.15\text{ mg/100g}} = 333,333\text{ grams} \approx 333.3\text{ kg (734 lbs)}$$
    *   **Verdict:** The estimate of **~150 lbs of grapes** represents a conservative, realistic midpoint for average-yield grocery store grapes.

---

### 2. Dihydromyricetin / DHM (SIRT3)
*   **Target Dose:** 300 mg
*   **Vine Tea (*Ampelopsis grossedentata*) Data:** Dried leaves of this specific plant are remarkably rich in DHM, frequently testing between **20% and 30% DHM by weight** in dry leaf samples. 
    *   **Calculation (at 20% DHM content):** 
        $$1.5\text{ grams of dry leaves} \times 0.20 = 0.3\text{ grams (300 mg) of DHM}$$
    *   **Calculation (at 30% DHM content):** 
        $$1.0\text{ gram of dry leaves} \times 0.30 = 0.3\text{ grams (300 mg) of DHM}$$
    *   **Verdict:** Because DHM is highly soluble in hot water, brewing **1.0 to 1.5 grams of dried leaves** will successfully yield roughly 300 mg of DHM. This makes vine tea one of the few natural sources where a therapeutic dose is highly practical to achieve in a single cup of tea.

---

### 3. Cyanidin-3-Glucoside / C3G (SIRT6)
*   **Target Dose:** 300 mg
*   **Blackberry Data:** The *Phenol-Explorer* database lists the mean concentration of cyanidin-3-glucoside in raw blackberries as **138.72 mg per 100 grams FW**, with a recorded minimum of **85.21 mg/100g FW**.
    *   **Calculation (at mean concentration):** 
        $$\frac{300\text{ mg}}{138.72\text{ mg/100g}} \approx 216\text{ grams of blackberries}$$
    *   **Calculation (at minimum concentration):** 
        $$\frac{300\text{ mg}}{85.21\text{ mg/100g}} \approx 352\text{ grams of blackberries}$$
    *   A standard cup of fresh blackberries weighs approximately 140 grams. 
        $$\frac{352\text{ grams}}{140\text{ grams/cup}} \approx 2.5\text{ cups}$$
    *   **Verdict:** Consuming **2 to 3 cups of blackberries** (roughly 315 to 375 grams) reliably covers the therapeutic threshold, even when accounting for low-yield cultivars.
*   **Black Elderberry Data:** *Phenol-Explorer* lists a mean C3G concentration of **794.13 mg per 100 grams FW**, and a minimum of **361.00 mg/100g FW**.
    *   **Calculation (at minimum concentration):** 
        $$\frac{300\text{ mg}}{361.00\text{ mg/100g}} \approx 83\text{ grams of elderberries}$$
    *   **Verdict:** The estimate of **70 to 85 grams of cooked elderberries** (roughly 1/2 to 2/3 cup) is mathematically verified to supply 300 mg of C3G.

---

### 4. Honokiol (SIRT3) — *A Solubility Correction*
Upon closer inspection of the physical chemistry, the raw tea estimate for Honokiol requires an important scientific clarification regarding **solubility**:

*   **Target Dose:** 200 mg
*   **Magnolia Bark Data:** Raw dried magnolia bark contains roughly 1% to 5% total biphenols (honokiol and magnolol combined).
*   **The Solubility Problem:** Unlike DHM, honokiol is highly lipophilic (oil-soluble) and has **extremely poor solubility in plain water**. 
    *   While 10 grams of raw bark technically contains plenty of honokiol, a traditional hot-water tea (decoction) will only extract a tiny fraction of it. 
    *   To get 200 mg of active honokiol into a consumable liquid, it must be extracted using solvents like ethanol (tinctures) or supercritical $CO_2$. 
    *   Attempting to brew enough water-based tea to reach 200 mg of bioavailable honokiol would require an excessively large, unsafe volume of raw bark.
*   **Verdict:** While the molecular math for the raw bark is correct, **honokiol cannot be effectively or safely dosed via standard water-brewed tea.** Standardized solvent-extracted supplements are required to bypass its poor water solubility.